BR112021021718A2 - Moduladores de thr-ss e métodos de uso dos mesmos - Google Patents
Moduladores de thr-ss e métodos de uso dos mesmosInfo
- Publication number
- BR112021021718A2 BR112021021718A2 BR112021021718A BR112021021718A BR112021021718A2 BR 112021021718 A2 BR112021021718 A2 BR 112021021718A2 BR 112021021718 A BR112021021718 A BR 112021021718A BR 112021021718 A BR112021021718 A BR 112021021718A BR 112021021718 A2 BR112021021718 A2 BR 112021021718A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- formula
- thr
- modulators
- fraction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
moduladores de thr-beta e métodos de uso dos mesmos. são divulgados neste documento compostos de fórmula (i): (i) tl-la-ce-hd ou um sal, pró-droga, amida ou éster farmaceuticamente aceitável do mesmo, em que i) tl é uma fração de fórmula iia, iib, iiia, iiib, iiic ou iiid; ii) ce é uma fração de fórmula iv; iii) hd é uma fração de fórmula v ou vi; onde os substituintes são como definidos neste documento. também são divulgadas composições farmacêuticas compreendendo os compostos acima e métodos de tratamento de doenças por administração ou contato de um paciente com um ou mais dos compostos acima.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962845252P | 2019-05-08 | 2019-05-08 | |
US201962944052P | 2019-12-05 | 2019-12-05 | |
US202063005661P | 2020-04-06 | 2020-04-06 | |
PCT/US2020/031904 WO2020227549A1 (en) | 2019-05-08 | 2020-05-07 | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021718A2 true BR112021021718A2 (pt) | 2022-01-18 |
Family
ID=70919081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021718A BR112021021718A2 (pt) | 2019-05-08 | 2020-05-07 | Moduladores de thr-ss e métodos de uso dos mesmos |
Country Status (17)
Country | Link |
---|---|
US (2) | US11091467B2 (pt) |
EP (1) | EP3965884A1 (pt) |
JP (1) | JP2022532706A (pt) |
KR (1) | KR20220017917A (pt) |
CN (1) | CN114096531A (pt) |
AU (1) | AU2020267576A1 (pt) |
BR (1) | BR112021021718A2 (pt) |
CA (1) | CA3139101A1 (pt) |
CL (1) | CL2021002883A1 (pt) |
CO (1) | CO2021015698A2 (pt) |
IL (1) | IL287720A (pt) |
MA (1) | MA55890A (pt) |
MX (1) | MX2021013472A (pt) |
PE (1) | PE20220255A1 (pt) |
SG (1) | SG11202111552YA (pt) |
TW (1) | TW202108569A (pt) |
WO (1) | WO2020227549A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
EP4083024A4 (en) * | 2019-11-26 | 2023-11-01 | KPC Pharmaceuticals, Inc. | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF |
WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
AU2021341182A1 (en) * | 2020-09-10 | 2023-04-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of resmetirom, preparation method therefor, and use thereof |
US11793815B2 (en) | 2020-11-06 | 2023-10-24 | Aligos Therapeutics, Inc. | Oxindoles and methods of use thereof |
EP4240484A1 (en) * | 2020-11-06 | 2023-09-13 | Aligos Therapeutics, Inc. | Pyridazinone derivatives as thyroid receptor agonists and uses thereof |
CN112645936B (zh) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
CA3212130A1 (en) * | 2021-03-03 | 2022-09-09 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1,2,4-三嗪-3,5-二酮类化合物的盐型、晶型及其制备方法 |
CN117279911A (zh) * | 2021-05-21 | 2023-12-22 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
WO2023023474A1 (en) * | 2021-08-16 | 2023-02-23 | Senya Pharmaceuticals, Inc. | Tr-beta modulators, pharmaceutical compositions, and therapeutic applications |
CA3230222A1 (en) | 2021-09-01 | 2023-03-09 | Leonid Beigelman | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
WO2023039076A1 (en) | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
CN116354934A (zh) * | 2021-12-28 | 2023-06-30 | 中国科学院上海药物研究所 | 一类喹啉类化合物及其制备方法、药物组合物和用途 |
CN115650928B (zh) * | 2022-12-28 | 2023-03-31 | 凯思凯旭(上海)医药科技有限公司 | 一种多环类甲状腺激素β受体激动剂及其用途 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
DE60020786T2 (de) * | 1999-09-30 | 2006-03-23 | Pfizer Products Inc., Groton | 6-Azauracilderivate als Liganden der Thyroidrezeptoren |
PT1262177E (pt) | 2001-05-31 | 2006-12-29 | Pfizer Prod Inc | Utilização medicinal de compostos tiromimético para tratamento da queda de cabelo e composições |
CA2473162A1 (en) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
WO2004047827A1 (en) | 2002-11-25 | 2004-06-10 | Pfizer Products Inc. | Method for promoting nail growth using thyromimetic compounds |
CA2614529C (en) * | 2005-07-21 | 2011-06-28 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives as thyroid hormone receptor agonists |
CA2634250A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
KR20090025367A (ko) * | 2006-06-28 | 2009-03-10 | 가부시키가이샤산와카가쿠켄큐쇼 | 신규 6-5계 이환식 복소환 유도체 및 그 의약용도 |
WO2008104752A1 (en) * | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
US8076334B2 (en) * | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
CN102459185B (zh) * | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
JP5847533B2 (ja) | 2010-10-19 | 2016-01-27 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
DK2695611T3 (en) | 2012-08-06 | 2015-01-05 | Wolff August Gmbh & Co Kg Arzneimittel Dr | Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions |
KR101966490B1 (ko) * | 2012-09-17 | 2019-08-14 | 마드리갈 파마슈티칼스, 인크. | 갑상선 호르몬 유사체 및 이의 다형의 합성 방법 |
US20160158200A1 (en) | 2013-07-09 | 2016-06-09 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
US10303567B2 (en) | 2013-08-15 | 2019-05-28 | Entit Software Llc | Managing database nodes |
GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
WO2016112305A1 (en) | 2015-01-09 | 2016-07-14 | Nimbus Apollo, Inc. | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
KR102444366B1 (ko) | 2016-06-03 | 2022-09-19 | 케모센트릭스, 인크. | 간 섬유화 치료 방법 |
WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
EP3595656A1 (en) | 2017-03-13 | 2020-01-22 | Genfit | Pharmaceutical compositions for combination therapy |
CA3058542A1 (en) | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
CN111183360A (zh) | 2017-07-19 | 2020-05-19 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
WO2019099457A1 (en) | 2017-11-14 | 2019-05-23 | Quixgen, Inc. | Benzodioxinone compounds |
KR20200096791A (ko) | 2017-12-06 | 2020-08-13 | 바스프 에이에스 | 비알콜성 지방간염 치료용 지방산 유도체 |
US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
US20210008020A1 (en) | 2018-03-12 | 2021-01-14 | Yale University | Methods of Treating or Preventing Acute Respiratory Distress Syndrome |
WO2019213611A1 (en) | 2018-05-04 | 2019-11-07 | Cirius Therapeutics, Inc. | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases |
CN108727344A (zh) * | 2018-05-14 | 2018-11-02 | 嘉兴特科罗生物科技有限公司 | 一种化合物及其合成方法和应用 |
EP3807267A4 (en) | 2018-06-12 | 2022-03-16 | Sichuan Haisco Pharmaceutical Co., Ltd. | THYROID HORMONE RECEPTOR AGONISTS AND ASSOCIATED USES |
CN112367979B (zh) | 2018-06-14 | 2024-05-03 | 博洛尼亚大学 | 用于局部释放抗炎药和促髓鞘药的电纺纤维 |
US20210292304A1 (en) | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
TW202019914A (zh) | 2018-07-02 | 2020-06-01 | 美商瑪德瑞高製藥公司 | 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式 |
US10800767B2 (en) | 2018-08-24 | 2020-10-13 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
WO2020073974A1 (en) | 2018-10-12 | 2020-04-16 | Inventisbio Shanghai Ltd. | Thyroid hormone receptor agonists |
US11203587B2 (en) | 2018-10-12 | 2021-12-21 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
EP3927693A4 (en) | 2019-02-21 | 2023-04-05 | Nanjing Ruijie Pharma Co., Ltd. | NOVEL COMPOUNDS AND THEIR USES AS THYROID HORMONE RECEPTOR AGONISTS |
WO2020227549A1 (en) * | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
IT201900006923A1 (it) | 2019-05-16 | 2020-11-16 | International Soc For Drug Development S R L | Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso |
TW202115029A (zh) | 2019-07-31 | 2021-04-16 | 大陸商深圳微芯生物科技股份有限公司 | 雜環化合物及其用途 |
WO2021032218A1 (zh) | 2019-08-19 | 2021-02-25 | 苏州闻天医药科技有限公司 | 一种并环THRβ受体激动剂化合物及其制备方法和用途 |
CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
CN114430743A (zh) | 2019-08-23 | 2022-05-03 | 拓臻制药公司 | 甲状腺激素受体β激动剂化合物 |
WO2021043185A1 (en) | 2019-09-04 | 2021-03-11 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
EP4028008A4 (en) | 2019-09-12 | 2023-09-13 | Terns Pharmaceuticals, Inc. | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS |
JP2022549009A (ja) | 2019-09-24 | 2022-11-22 | ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 | 甲状腺ホルモンベータ受容体アゴニストとしての化合物及びその使用 |
-
2020
- 2020-05-07 WO PCT/US2020/031904 patent/WO2020227549A1/en unknown
- 2020-05-07 AU AU2020267576A patent/AU2020267576A1/en active Pending
- 2020-05-07 SG SG11202111552YA patent/SG11202111552YA/en unknown
- 2020-05-07 JP JP2021566558A patent/JP2022532706A/ja active Pending
- 2020-05-07 MA MA055890A patent/MA55890A/fr unknown
- 2020-05-07 KR KR1020217039735A patent/KR20220017917A/ko unknown
- 2020-05-07 US US16/869,211 patent/US11091467B2/en active Active
- 2020-05-07 PE PE2021001847A patent/PE20220255A1/es unknown
- 2020-05-07 CA CA3139101A patent/CA3139101A1/en active Pending
- 2020-05-07 CN CN202080047744.2A patent/CN114096531A/zh active Pending
- 2020-05-07 MX MX2021013472A patent/MX2021013472A/es unknown
- 2020-05-07 BR BR112021021718A patent/BR112021021718A2/pt unknown
- 2020-05-07 EP EP20729390.3A patent/EP3965884A1/en active Pending
- 2020-05-08 TW TW109115446A patent/TW202108569A/zh unknown
-
2021
- 2021-05-25 US US17/330,232 patent/US20210355112A1/en active Pending
- 2021-10-31 IL IL287720A patent/IL287720A/en unknown
- 2021-11-03 CL CL2021002883A patent/CL2021002883A1/es unknown
- 2021-11-23 CO CONC2021/0015698A patent/CO2021015698A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022532706A (ja) | 2022-07-19 |
IL287720A (en) | 2021-12-01 |
WO2020227549A1 (en) | 2020-11-12 |
CN114096531A (zh) | 2022-02-25 |
SG11202111552YA (en) | 2021-11-29 |
MX2021013472A (es) | 2022-01-06 |
US20200354345A1 (en) | 2020-11-12 |
CA3139101A1 (en) | 2020-11-12 |
WO2020227549A8 (en) | 2021-05-27 |
US11091467B2 (en) | 2021-08-17 |
TW202108569A (zh) | 2021-03-01 |
MA55890A (fr) | 2022-03-16 |
AU2020267576A1 (en) | 2021-12-09 |
CL2021002883A1 (es) | 2022-10-28 |
KR20220017917A (ko) | 2022-02-14 |
CO2021015698A2 (es) | 2022-01-17 |
PE20220255A1 (es) | 2022-02-16 |
EP3965884A1 (en) | 2022-03-16 |
US20210355112A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021718A2 (pt) | Moduladores de thr-ss e métodos de uso dos mesmos | |
CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
BR112021024131A2 (pt) | Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo | |
BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
AR058338A1 (es) | Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa. | |
BR112014009102A2 (pt) | compostos químicos | |
CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
BR112019006778A2 (pt) | Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
CY1124346T1 (el) | ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ | |
BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
BR112015028760A2 (pt) | compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas | |
BR112017008794A2 (pt) | inibidores de di-heteroaril histona desacetilase e seu uso em terapia | |
BR112021011325A2 (pt) | Derivados de rapamicina | |
CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
BR112022010638A2 (pt) | Compostos para modular a atividade de fxr e usos dos mesmos | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
BR112018015191A2 (pt) | compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida |